Arca
Skip to content
Tools
Tools

XPO1: Exportin-1

Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on XPO1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Selinexor

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        SelinexorApprovedKaryopharm TherapeuticsSmall moleculeInhibitorExportin-1 inhibitor87

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialSelinexorPhase 2Not yet recruitingDana-Farber Cancer InstituteSep 21, 2026
        A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCTSelinexorPhase 1 / Phase 2Active, not recruitingLiping DouAug 21, 2026
        Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac AmyloidosisSelinexorPhase 2Not yet recruitingBeijing Anzhen HospitalAug 4, 2026
        New Genotype-guided Treatment in Newly Diagnosed PTCLSelinexorPhase 1 / Phase 2Not yet recruitingRuijin HospitalJul 16, 2026
        Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaSelinexor—Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineJun 25, 2026
        The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 MutationsSelinexorNot applicableNot yet recruitingBing HanJun 8, 2026
        Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative NeoplasmsSelinexorPhase 2Not yet recruitingZhongshan Hospital (Xiamen), Fudan UniversityJun 4, 2026
        A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003SelinexorPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jun 3, 2026

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Plasma cell myeloma0.64
        • HIV infectious disease0.56
        • Neurodegenerative disease0.52
        • Alzheimer disease0.48
        • Parkinson disease0.47
        • Orthomyxoviridae infectious disease0.47
        • Lysosomal storage disease0.46
        • Neoplasm0.40

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5661, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O14980, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.